Free Trial

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Moderate Buy" by Brokerages

Syndax Pharmaceuticals logo with Medical background

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $35.91.

Several brokerages recently weighed in on SNDX. HC Wainwright reaffirmed a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Guggenheim reaffirmed a "buy" rating and issued a $32.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Citigroup cut their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Scotiabank lifted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. increased their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research note on Thursday, March 20th.

Check Out Our Latest Research Report on Syndax Pharmaceuticals

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock traded up $0.03 during midday trading on Friday, hitting $9.22. 2,865,381 shares of the company's stock were exchanged, compared to its average volume of 1,811,127. The firm's 50 day simple moving average is $11.06 and its 200 day simple moving average is $12.73. Syndax Pharmaceuticals has a 12-month low of $8.58 and a 12-month high of $25.07. The company has a debt-to-equity ratio of 1.53, a quick ratio of 5.75 and a current ratio of 5.80. The stock has a market cap of $793.38 million, a price-to-earnings ratio of -2.39 and a beta of 0.74.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The firm had revenue of $20.04 million for the quarter, compared to analyst estimates of $15.88 million. Syndax Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 757.53%. The business's revenue was up 1900.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.85) earnings per share. Equities research analysts predict that Syndax Pharmaceuticals will post -3.72 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SNDX. Quarry LP acquired a new stake in shares of Syndax Pharmaceuticals during the first quarter valued at $25,000. Virtus ETF Advisers LLC boosted its stake in shares of Syndax Pharmaceuticals by 18.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after purchasing an additional 827 shares during the last quarter. Cape Investment Advisory Inc. grew its holdings in shares of Syndax Pharmaceuticals by 157.1% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,427 shares of the company's stock worth $85,000 after buying an additional 3,927 shares in the last quarter. Magnetar Financial LLC acquired a new position in shares of Syndax Pharmaceuticals in the first quarter valued at approximately $132,000. Finally, Optimize Financial Inc purchased a new position in shares of Syndax Pharmaceuticals during the fourth quarter valued at approximately $152,000.

Syndax Pharmaceuticals Company Profile

(Get Free Report

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

See Also

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?

Before you consider Syndax Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.

While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines